Category: Articles
-

Hope for New Prognostic Biomarkers & Therapeutic Options From Tumour Metabolism-Targeting Breast Cancer Study
Understanding the interplay between the tumour microenvironment and immunometabolic states could unlock a wealth of therapeutic targets and biomarkers. Read More
-

Liquid Biopsy for Early-Stage Pancreatic Cancer, Data Presented at AACR
Earlier detection of pancreatic cancer could increase five year survival from 3% to 44%. Read More
-

Finding New Immunotherapy Targets for Solid Brain Tumour CAR Ts with RNAseq in Cancer-Specific Exons
The project has found over 150 target candidates for solid brain tumour therapies. Read More
-

“World’s First” IND Approval for Epstein-Barr mRNA Cancer Vaccine
Epstein-Barr virus has been highly linked to over ten forms of cancer. This wide range of malignant implications means an expanded variety of target indications for the vaccine. Read More
-

New Zika-Specific Synthetic Biomarker Can Differentiate From Dengue Virus
A test that identifies Zika distinct from dengue could make a definite impact to expectant mothers and reproductive-age women that are at risk from the mosquito-borne disease. Read More
-

Patients Enter Clinic for Phase III mRNA Immunotherapy for High Risk Melanoma
The trial will test the world’s first mRNA-based personalised immunotherapy for melanoma. Read More
-

First Patient Dosed with NK Cell Therapy for the Treatment of an Autoimmune Disease, Lupus Nephritis
The NK cell therapy is being trialled in combination with monoclonal antibody therapy and hopes to induce B-cell depletion. Read More
-

Blood Test for Alzheimer’s Granted Breakthrough Device Status by FDA
A blood test for the phosphorylated protein pTau-217 could be a critical step towards early diagnosis and screening of Alzheimer’s disease. Read More
-

Pianno: a Model for the Annotation of Spatial Transcriptomics Data
The model has unveiled insights on the evolution and diversification of the cell types of the brain. Read More
-

Merus’s Preclinical Bispecific Zeno Demonstrates Efficacy in Cancer Models
Zeno interrupts the dimerization of HER2 and HER3 and prevents NRG1/HER3 tumour signalling. Read More
